FASTx program

Fort Worth’s TFF Pharmaceuticals Partners to Develop Dry Powder-Inhaled mRNA Treatment for Flu and COVID

by | Sep 13, 2024
Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral drugs to combat them. TFF is now partnering with Atlanta's Emory University and the Biomedical Advanced Research and Development Authority (BARDA) to test the feasibility of converting an Emory-developed mRNA antiviral into a dry powder formulation that needs no cold-chain storage.
MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.